Gastroenterology

Dapagliflozin shows positive impact on type 2 diabetes and non-alcoholic fatty liver disease

Dapagliflozin demonstrates significant benefits in improving hepatic function and glucose control in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), according to a meta-analysis. The study, which included 4 randomized controlled trials, found that dapagliflozin treatment led to a notable reduction in key markers such as alanine...